Pharmaceutical

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone…

1 year ago

MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory

VANCOUVER, BC / ACCESSWIRE / August 1, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a leading biopharmaceutical…

1 year ago

Glaukos Announces Second Quarter 2024 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the…

1 year ago

Glaukos Announces Second Quarter 2024 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the…

1 year ago

TwinStrand Biosciences and Exact Sciences Announce Exclusive License Agreement for Duplex Sequencing Technology

SEATTLE, July 31, 2024 /PRNewswire/ -- TwinStrand Biosciences today announced an agreement with Exact Sciences (Nasdaq: EXAS), a leading provider…

1 year ago

Revolutionary FlackTek™ Technology Enhances Solvent Purging Process in Cannabis Extracts

LANDRUM, S.C., July 31, 2024 /PRNewswire/ -- A groundbreaking study conducted by Cambium Analytica, a leader in analytical testing, product…

1 year ago

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024

RANCHO CUCAMONGA, CA / ACCESSWIRE / July 31, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release…

1 year ago

Vaniam Group™ Accelerates Innovation With Appointment of Industry Leader Steve Tulk as Chief Technology Officer

Mr Tulk will spearhead innovative digital solutions, advanced analytics, and new offerings for Vaniam Group's clients. CHICAGO, July 31, 2024 /PRNewswire/…

1 year ago

Inoviv Launches MasterKey™, A Customizable Platform for Multiplexed Targeted Protein Assays, Leveraging a Pre-Characterized Database of Thousands of Proteins

MasterKey™ enables researchers to customize protein selection from a vast database, selecting 50+ proteins for quantitative multiplex assays.MasterKey™ leverages advanced…

1 year ago